SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- Forge Therapeutics, Inc., a biotechnology company discovering first-in-class therapeutics using a breakthrough drug discovery platform, announced today that Zachary A. Zimmerman, Ph.D., CEO of Forge, will present an update on its technology platform, research programs, and business outlook at the BIOCOM Life Science Partnering Conference on Wednesday, March 1, 2017, at 3:00 pm PT at the Torrey Pines Lodge in San Diego, CA.
"Each year, approximately twenty-three thousand deaths are attributed to drug resistant bacteria in the United States, which leads to a crushing $20 billion burden on our healthcare system. Resistant bacteria are clearly plentiful, but unfortunately, new drugs are extremely scarce," said Zachary A. Zimmerman, Ph.D., CEO of Forge. "At Forge, we have leveraged our novel chemistry platform to develop a first-in-class, Gram-negative bacteria program targeting LpxC, that we feel has extreme promise to solve this global health epidemic. We are thankful to the organizers of the BIOCOM conference for the opportunity to showcase our technology and shine a light on the importance of the development of new, life-saving antibiotics."